From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascularendothelialgrowthfactor (VEGF) inhibition .
ZD-4190 is a potent, orally available inhibitor of the vascularendothelial cell growthfactor receptor 2 (VEGFR2) and of epidermal growthfactor receptor (EGFR) signalling, used for the treatment of cancer.
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growthfactor receptor (PDGFR) and vascularendothelialgrowthfactor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .
Low molecular weight protamine is a cell-penetrating peptide with vascularendothelialgrowthfactor (VEGF) inhibitory activity. Low molecular weight protamine can inhibit tumor growth and is used in cancer research .
Pegaptanib sodium is an RNA aptamer directed against vascularendothelialgrowthfactor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
BHEPN is an inhibitor of vascularendothelialgrowthfactor receptor-2 (VEGFR-2). BHEPN has inhibition of VEGFR-2 with an IC50 value of 0.320 μM. BHEPN also exhibits remarkable cytotoxic effects against HepG2 and MCF-7 cancer cell lines, with IC50 values of 0.19 μM and 1.18 μM, respectively. BHEPN can be used for anticancer research .
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascularendothelialgrowthfactor (VEGF). It is widely accepted that vascularendothelialgrowthfactor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
Bevasiranib is a siRNA designed to silence the genes that produce vascularendothelialgrowthfactor (VEGF). It is widely accepted that vascularendothelialgrowthfactor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
VEGFR-IN-6 (Compound 3) is a vascularendothelialgrowthfactor receptor (VEGFR) inhibitor. VEGFR-IN-6 can inhibit angiogenesis. VEGFR-IN-6 is promising for research of tumor diseases that rely on angiogenesis .
YLL545 is a type of vascularendothelialgrowthfactor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth .
Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 (COX-2) and vascularendothelialgrowthfactor (VEGF). PGV-1 inhibits NF-κB activation .
SLMP53-1 is a wild-type and mutant p53 reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascularendothelialgrowthfactor (VEGF) expression levels .
SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascularendothelialgrowthfactor receptor 2 (VEGFR2) .
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascularendothelialgrowthfactor (VEGF) inhibitor .
Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascularendothelialgrowthfactor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy .
Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascularendothelialgrowthfactor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy .
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascularendothelialgrowthfactor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascularendothelialgrowthfactor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growthfactor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascularendothelialgrowthfactor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2) .
Pumitamig is a humanized bispecific immunoglobulin (H-γ1-VH_L-κ) dimer antibody targeting human vascularendothelialgrowthfactor A (VEGFA) and human programmed death ligand 1 (PD-L1). Pumitamig is promising for research of various solid tumors .
Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascularendothelialgrowthfactor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy .
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascularendothelialgrowthfactor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .
UniPR1331 is a 3β-hydroxy-Δ5-choline acid derivative that inhibits Eph-ephrin interactions. UniPR1331 interacts with VEGFR2 and blocks the interaction of VEGFR2 with its natural ligand vascularendothelialgrowthfactor and subsequent autophosphorylation, signaling, and pro-angiogenic activation of endothelial cells in vitro. UniPR1331 also inhibits tumor cell-driven angiogenesis in zebrafish .
Ziv-aflibercept is a soluble inhibitor of vascularendothelialgrowthfactor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .
CPD-002 is an inhibitor for vascularendothelialgrowthfactor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis .
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascularendothelialgrowthfactor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growthfactor (HGF) receptor c-MET and vascularendothelialgrowthfactor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
Oglufanide (H-Glu-Trp-OH) disodium is a dipeptide immunomodulator isolated from calf thymus. Oglufanide disodium inhibits vascularendothelialgrowthfactor (VEGF). Oglufanide disodium can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide disodium shows antitumor and anti-angiogenesis activities .
Chloramphenicol (Standard) is the analytical standard of Chloramphenicol. This product is intended for research and analytical applications. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascularendothelialgrowthfactor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .
(Z)-FeCP-oxindole is a selective human vascularendothelialgrowthfactor receptor 2 (VEGFR2) inhibitor with an IC50 value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC50 less than 1 μM .
Tivozanib-d6 (AV-951-d6) is deuterium labeled Tivozanib. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascularendothelialgrowthfactor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy .
(Z)-FeCP-oxindole is a selective human vascularendothelialgrowthfactor receptor 2 (VEGFR2) inhibitor with an IC50 value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC50 less than 1 μM .
Threo-Chloramphenicol-d6 is the deuterium labeled Chloramphenicol[1]. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascularendothelialgrowthfactor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research[2][3][4].
YF-452 is a potent inhibitor of vascularendothelialgrowthfactor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research .
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascularendothelialgrowthfactor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .
Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of VascularEndothelialGrowthFactor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast GrowthFactor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .
6,8-Diprenylgenistein is an isoflavone compound isolated from Cudrania tricuspidata. 6,8-Diprenylgenistein has antimicrobial and anti-obesity activity. 6,8-Diprenylgenistein inhibits the proliferation, migration and tubular formation of HLMEC induced by recombinant human vascularendothelialgrowthfactor-A. 6,8-Diprenylgenistein can be used to study new therapeutic drugs for the prevention and treatment of oral cancer metastasis .
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .
(rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascularendothelialgrowthfactor receptor kinases (VEGF-RTKs), and platelet-derived growthfactor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET .
NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC50 values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity . NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase with IC50 values of 17 nM and 20 nM . NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells with an IC50 of 30 nM . NS-2028 is commonly used in the research of nitric oxide signaling pathways, it inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM) . NS-2028 reduces vascularendothelialgrowthfactor-induced angiogenesis and permeability .
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascularendothelialgrowthfactor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascularendothelialgrowthfactor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .
C-VGB3 is a selective vascularendothelialgrowthfactor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer .
HC-5404-Fu is a PERK inhibitor with an antitumor activity. HC-5404-Fu inhibits endoplasmic reticulum stress response signalling. HC-5404-Fu sensitizes renal cell carcinoma cells to vascularendothelialgrowthfactor (VEGF) receptor tyrosine kinase inhibitors (TKIs). HC-5404-Fu is promising for research of renal cell carcinoma, gastric cancer, metastatic breast cancer, small cell lung cancer, and other solid tumors .
CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC50 value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascularendothelialgrowthfactor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK). CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma .
Atiprimod (Azaspirane) is an orally bioavailable small molecule with antitumor, anti-inflammatory, and anti-angiogenic activities. Atiprimod blocks the signaling pathways of interleukin-6 and vascularendothelialgrowthfactor (VEGF) by inhibiting the phosphorylation of signal transducer and activator of transcription 3 (STAT3). Atiprimod also downregulates the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis. Atiprimod triggers persistent ER stress-mediated apoptosis in breast cancer cells by activating the PERK/eIF2α/ATF4/CHOP axis and inhibiting the nuclear translocation of STAT3/NF-κB transcription factors .
TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascularendothelialgrowthfactor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .
Siphonaxanthin is a keto-carotenoid with anti-angiogenic activity, which is found in green algae. Siphonaxanthin targets death receptor 5 (DR5) and induces apoptosis in cancer cells. Siphonaxanthin upregulates the expression of DR5, decreases the expression of Bcl-2, and activates caspase-3 in human leukemia HL-60 cells. Siphonaxanthin is an inhibitor of fibroblast growthfactor receptor-1 (FGFR-1) signaling transduction in vascularendothelial cells. Siphonaxanthin inhibits the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs), as well as the outgrowth of microvessels in the rat aortic ring. Siphonaxanthin can also inhibit the translocation of the high-affinity IgE receptor (FcεRI) to lipid rafts in mast cells, acting as an anti-inflammatory agent. Siphonaxanthin is promising for research of diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis .
VEGFR-2-IN-67 (Compound 6b) is an inhibitor of vascularendothelialgrowthfactor receptor 2 (VEGFR-2). Its IC50 values for MDA-231 and MCF-7 cell lines are 5.91 µM and 7.16 µM respectively, and its inhibitory effect on VEGFR-2 is comparable to that of Sorafenib (HY-10201) (IC50 is 53.63 nM). VEGFR-2-IN-67 exerts significant anti-cancer activity through mechanisms such as inducing Apoptosis (the early apoptosis rate reaches 57.20%), arresting the cell cycle at the G1 phase, upregulating pro-apoptotic markers and downregulating Bcl-2. VEGFR-2-IN-67 can be used for research in the field of cancer .
CEP-7055 (compound 21) is a novel vascularendothelialgrowthfactor R2 (VEGF-R2) tyrosine kinase inhibitor with potent inhibitory activity. Studies have found that the inhibitor activity can be significantly improved by optimizing the R9 substituent. Compound 21 has potent low nanomolar inhibition of human VEGF-R tyrosine kinase and shows good selectivity against multiple tyrosine and serine/threonine kinases. N,N-dimethylglycine ester 40 was prepared to improve its water solubility and oral bioavailability. In animal pharmacokinetic studies, a significant increase in the plasma level of 21 was observed after oral administration of 40. Compound 21 showed significant in vivo antitumor activity in multiple tumor models and has entered phase I clinical trials as a water-soluble N,N-dimethylglycine ester proagent of 40 (CEP-7055).
CEP-5214, derived from a new indenopyrrolocarbazole template, is a potent inhibitor of vascularendothelialgrowthfactor R2 (VEGF-R2) tyrosine kinase. Structurally, it features optimal substitutions at positions 9 (ethoxymethyl) and 12 (hydroxypropyl) on the indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-one scaffold, leading to high potency against VEGF-R2 (IC50 8 nM). Compound 21 (CEP-5214) exhibits low-nanomolar inhibition of human VEGF-R tyrosine kinases (IC50 4 nM for VEGF-R2/KDR), with good selectivity over other kinases. The compound demonstrated significant cellular and in vivo antitumor activity across various models and advanced into phase I clinical trials as a water-soluble prodrug (CEP-7055) to enhance oral bioavailability .
VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascularendothelialgrowthfactor (VEGF), basic fibroblast growthfactor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer).
MCE offers a unique collection of 2,645 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.
Low molecular weight protamine is a cell-penetrating peptide with vascularendothelialgrowthfactor (VEGF) inhibitory activity. Low molecular weight protamine can inhibit tumor growth and is used in cancer research .
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascularendothelialgrowthfactor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .
TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascularendothelialgrowthfactor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .
Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascularendothelialgrowthfactor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .
C-VGB3 is a selective vascularendothelialgrowthfactor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer .
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascularendothelialgrowthfactor (VEGF) inhibition .
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a vascularendothelialgrowthfactor (VEGF) inhibitor .
Ziv-aflibercept is a soluble inhibitor of vascularendothelialgrowthfactor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascularendothelialgrowthfactor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascularendothelialgrowthfactor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
Pumitamig is a humanized bispecific immunoglobulin (H-γ1-VH_L-κ) dimer antibody targeting human vascularendothelialgrowthfactor A (VEGFA) and human programmed death ligand 1 (PD-L1). Pumitamig is promising for research of various solid tumors .
Oglufanide (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascularendothelialgrowthfactor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities .
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascularendothelialgrowthfactor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .
Chloramphenicol (Standard) is the analytical standard of Chloramphenicol. This product is intended for research and analytical applications. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascularendothelialgrowthfactor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .
Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascularendothelialgrowthfactor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2) .
6,8-Diprenylgenistein is an isoflavone compound isolated from Cudrania tricuspidata. 6,8-Diprenylgenistein has antimicrobial and anti-obesity activity. 6,8-Diprenylgenistein inhibits the proliferation, migration and tubular formation of HLMEC induced by recombinant human vascularendothelialgrowthfactor-A. 6,8-Diprenylgenistein can be used to study new therapeutic drugs for the prevention and treatment of oral cancer metastasis .
The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (P.pastoris) is the recombinant rat-derived VEGF164 protein, expressed by P. pastoris , with tag free and A36T mutation.
The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (His-SUMO) is the recombinant Rabbit-derived VEGF-A protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
VEGF-A Protein is a key member of the VEGF family of cytokines.VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability.VEGF-A stimulates endothelial cell mitogenesis and cell migration.VEGF120 Protein, Mouse is the recombinant mouse-derived VEGF120 protein, expressed by E.coli , with tag free.
VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF121 Protein, Human (HEK293, His) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-6*His labeled tag.
The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (P. pastoris, His) is the recombinant Rabbit-derived VEGF-A protein, expressed by P. pastoris , with N-6*His labeled tag.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-CC Protein, Human (196a.a, HEK293, His) is the recombinant human-derived VEGF-CC protein, expressed by HEK293 , with C-6*His labeled tag.
VEGFA Protein is a vascular endothelial growth factor that is active in angiogenesis and endothelial cell growth. VEGFA Protein induces endothelial cell proliferation, promotes cell migration, inhibits cell apoptosis, and induces vascular permeability. VEGFA Protein consists of 214 amino acids (M1-R214). VEGF-AA Protein, Canine (HEK293) is the recombinant canine-derived VEGF-AA protein, expressed by HEK293 , with tag free.
The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (sf9) is the recombinant rat-derived VEGF164 protein, expressed by Sf9 insect cells , with tag free.
VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF183 Protein, Human (sf9) is the recombinant human-derived VEGF183 protein, expressed by Sf9 insect cells , with tag free.
The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Pig (His) is the recombinant pig-derived VEGF-A protein, expressed by E. coli , with N-6*His labeled tag.
VEGF-DD protein is a potent growth factor in angiogenesis, lymphangiogenesis, and endothelial cell growth, playing a key role in stimulating cell proliferation, migration, and affecting vascular permeability. It may be involved in the formation of veins and lymphatic vasculature during embryogenesis, suggesting that it plays a key role in vascular development. VEGF-DD Protein, Human (HEK293, His) is the recombinant human-derived VEGF-DD protein, expressed by HEK293 , with C-6*His labeled tag.
VEGF-DD Protein, a versatile growth factor, orchestrates angiogenesis, lymphangiogenesis, and endothelial cell growth. It stimulates proliferation, migration, and influences vessel permeability. VEGF-DD binds VEGFR-3, triggering crucial signaling for vascular development. Structurally, VEGF-DD is a non-covalent homodimer, emphasizing its intricate role in vascular processes. VEGF-DD Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGF-DD protein, expressed by HEK293 , with C-6*His labeled tag.
VEGF-BB protein is an endothelial cell-specific growth factor with VEGF-B167 and VEGF-B186 isoforms and has a unique binding ability to heparin and Neuropilin-1. VEGF-BB Protein, Human (HEK293, Fc) is the recombinant human-derived VEGF-BB protein, expressed by HEK293 , with N-hFc labeled tag.
VEGF-DD Protein, a versatile growth factor, orchestrates angiogenesis, lymphangiogenesis, and endothelial cell growth. It stimulates proliferation, migration, and influences vessel permeability. VEGF-DD binds VEGFR-3, triggering crucial signaling for vascular development. Structurally, VEGF-DD is a non-covalent homodimer, emphasizing its intricate role in vascular processes. VEGF-DD Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived VEGF-DD protein, expressed by HEK293 , with N-hFc labeled tag.
VEGF-DD, a growth factor, stimulates proliferation, migration, and vessel permeability. It is crucial for vascular development and maintenance of lymphatic endothelium. VEGF-DD binds and activates VEGFR-3, initiating essential signaling pathways. Structurally, it forms a non-covalent homodimer, playing an intricate role in vascular processes. VEGF-DD Protein, Rat (HEK293, Fc) is the recombinant rat-derived VEGF-DD protein, expressed by HEK293 , with N-hFc labeled tag.
The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. Animal-Free VEGF Protein, Pig (His) is the recombinant pig-derived animal-FreeVEGF protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.
VEGF-A Protein is a key member of the VEGF family of cytokines.VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability.VEGF-A stimulates endothelial cell mitogenesis and cell migration.VEGF164 Protein, Mouse (P.pastoris) is the recombinant mouse-derived VEGF164 protein, expressed by P.pastoris , with tag free.
VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF121 Protein, Human (HEK293) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with tag free.
VEGF-CC protein stimulates cell proliferation, migration, and vascular permeability, which are critical for angiogenesis and endothelial cell dynamics. It plays a crucial role in the development of the venous and lymphatic vasculature during embryogenesis and in the maintenance of adult lymphatic endothelium. VEGF-CC Protein, Mouse/Rat (HEK293, His) is the recombinant mouse, rat-derived VEGF-CC protein, expressed by HEK293 , with C-6*His labeled tag.
VEGF-CC protein stimulates cell proliferation, migration, and vascular permeability, which are critical for angiogenesis and endothelial cell dynamics. It plays a crucial role in the development of the venous and lymphatic vasculature during embryogenesis and in the maintenance of adult lymphatic endothelium. VEGF-CC Protein, Mouse/Rat (HEK293, Fc) is the recombinant rat, mouse-derived VEGF-CC protein, expressed by HEK293 , with N-hFc labeled tag.
VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF165 Protein, Human (HEK293, C-His) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with C-10*His labeled tag.
VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF145 Protein, Human (HEK293, solution) is the recombinant human-derived VEGF145 protein, expressed by HEK293 , with tag free.
VEGF-C Protein, Human (116a.a, HEK293) functions in lymphangiogenesis, where it acts on lymphatic endothelial cells (LECs) primarily via its receptor VEGFR-3 promoting survival, growth and migration.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-CC Protein, Human (125a.a, HEK293, His) is the recombinant human-derived VEGF-CC protein, expressed by HEK293 , with C-His labeled tag.
VEGF145 Protein, with limited expression, exhibits specialized distribution and is not broadly present in tissues. Its restricted occurrence implies a specific, context-dependent role in physiological processes. Further research is needed to unveil the specific cellular contexts and functions where VEGF145 actively participates, providing insights into its potential contributions to localized biological activities. VEGF121 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
VEGFR-1 protein is a tyrosine protein kinase receptor for VEGFA, VEGFB, and PGF and is critical for embryonic vasculature development, angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer invasion. It actively regulates postnatal retinal vitreous vascular degeneration and may act as a negative regulator of embryonic angiogenesis. VEGFR-1 Protein, Rat (HEK293, His) is the recombinant rat-derived VEGFR-1 protein, expressed by HEK293 , with C-His labeled tag.
The VEGFR-1 protein is a key tyrosine protein kinase receptor. VEGFR-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGFR-1 protein, expressed by HEK293 , with C-His, C-10*His labeled tag.
VEGFR-3/FLT4 proteins are tyrosine protein kinase receptors for VEGFC and VEGFD and are critical in adult lymphangiogenesis and embryonic vascular development. It promotes endothelial cell function, angiogenesis, and forms a positive feedback loop that increases VEGFC production. VEGFR-3/FLT4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-His labeled tag.
VEGFR-3/FLT4 proteins are tyrosine protein kinase receptors for VEGFC and VEGFD and are critical in adult lymphangiogenesis and embryonic vascular development. It promotes endothelial cell function, angiogenesis, and forms a positive feedback loop that increases VEGFC production. VEGFR-3/FLT4 Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-hFc labeled tag.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-His labeled tag.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, hFc) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-hFc labeled tag.
VEGFR-2 Protein is a type III receptor tyrosine kinase, also known as the receptor for vascular endothelial growth factor 2. VEGFR-2 Protein mediates vascular endothelial growth factor (VEGF)-induced endothelial proliferation, survival, migration, tubular morphogenesis, and sprouting, and plays a key role in angiogenesis and vasculogenesis. VEGFR-2 Protein, Rat (HEK293, His) is the recombinant rat-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag.
VEGFR-2 protein is an important tyrosine protein kinase receptor.As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis.It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization.VEGFR-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-C Protein, Human (116a.a, HEK293, His) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-6*His labeled tag.
VEGFR-2 Protein is a type III receptor tyrosine kinase, also known as the receptor for vascular endothelial growth factor 2.VEGFR-2 Protein mediates vascular endothelial growth factor (VEGF)-induced endothelial proliferation, survival, migration, tubular morphogenesis, and sprouting, and plays a key role in angiogenesis and vasculogenesis.VEGFR-2 Protein, Rat (HEK293, Fc) is the recombinant rat-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.
VEGFR-2 protein is an important tyrosine protein kinase receptor.As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis.It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization.VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-6*His labeled tag.
The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (328a.a, HEK293, Fc) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-hFc labeled tag.
The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (328a.a, HEK293, His) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-His labeled tag.
The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (756a.a, HEK293, His) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-His labeled tag.
VEGFR-2 protein is an important tyrosine protein kinase receptor.As a cell surface receptor for VEGFA, VEGFC and VEGFD, it plays an important role in the regulation of angiogenesis, vascular development, permeability and embryonic hematopoiesis.It actively promotes endothelial cell proliferation, survival, migration, differentiation, and actin cytoskeletal reorganization.VEGFR-2 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (327a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (208a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.
The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (730a.a, HEK293, Fc) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-hFc labeled tag.
TL1A/TNFSF15 Protein, the receptor for TNFRSF25 and TNFRSF6B, activates NF-kappa-B and promotes caspase activation, leading to apoptosis. It also inhibits vascular endothelial growth and angiogenesis in vitro. Operating as a homotrimer, it plays a crucial role in diverse cellular processes, including immune response and apoptosis regulation. TL1A/TNFSF15 Protein, Human (O95150-2, HEK293, His) is the recombinant human-derived TL1A/TNFSF15 protein, expressed by HEK293 , with labeled tag.
TL1A/TNFSF15 Protein, the receptor for TNFRSF25 and TNFRSF6B, activates NF-kappa-B and promotes caspase activation, leading to apoptosis. It also inhibits vascular endothelial growth and angiogenesis in vitro. Operating as a homotrimer, it plays a crucial role in diverse cellular processes, including immune response and apoptosis regulation. TL1A/TNFSF15 Trimer Protein, Human (HEK293, His) is the recombinant human-derived TL1A/TNFSF15 Trimer protein, expressed by HEK293 , with N-His labeled tag.
The TL1A protein (VEGI protein), belongs to the tumor necrosis factor (TNF) family and is a receptor for TNFRSF25 and TNFRSF6B. TL1A is involved in the activation of NF-κB and C-Jun pathways, which can be used as a regulator of mucosal immunity and participate in the immune pathway of inflammatory bowel disease (IBD) pathogenesis. TL1A originates from endothelial cells and inhibits the proliferation of breast cancer, epithelial and myeloid tumor cells. The mouse TL1A protein has a transmembrane domain (40-60 a.a.) that can be cleaved into membrane-type and soluble peptide fragments. TL1A/TNFSF15 Protein, Mouse is the extracullar part of TL1A protein (I76-L252), produced in E.coli with tag free.
VEGFR-2 is a tyrosine-protein kinase of the cell surface receptors of VEGFA, VEGFC, and VEGFD that mediates activation of the MAPK1/ERK2, MAPK3/ERK1, and MAP kinase signaling pathways, as well as the AKT1 signaling pathway. VEGFR-2 can promote the proliferation, survival, migration and differentiation of endothelial cells. Overexpression of VEGFR-2 is associated with the development of tumors. VEGFR-2 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-His labeled tag.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
Neuropilin-1 protein is a cell surface receptor that plays multiple roles in cardiovascular development, angiogenesis, and neuronal circuit formation. It mediates chemical repulsion by recognizing ligands with CendR motifs, leading to internalization and vascular leakage. Neuropilin-1 Protein, Rat (HEK293, His) is the recombinant rat-derived Neuropilin-1 protein, expressed by HEK293 , with C-6*His labeled tag and K811R, P812-G828 delet.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (745a.a, HEK293, Fc) is the recombinant human-derived VEGFR-2 protein, expressed by HEK293 , with C-hFc labeled tag.
VEGFR-2 protein is a tyrosine protein kinase receptor for VEGFA, VEGFC and VEGFD and is critical in angiogenesis, blood vessel development and embryonic hematopoiesis. It promotes endothelial cell function and actin cytoskeletal reorganization. VEGFR-2 Protein, Human (1355a.a, sf9, GST) is the recombinant human-derived VEGFR-2, expressed by Sf9 insect cells , with GST labeled tag. ,
VEGF165 Protein, Human (P.pastoris) is a Vascular Endothelial Growth Factor A (VEGF-A) isoform. VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis.
VEGF165 Protein, Human (HEK293) is a Vascular Endothelial Growth Factor A (VEGF-A) isoform. VEGF is a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis.
Tivozanib-d6 (AV-951-d6) is deuterium labeled Tivozanib. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascularendothelialgrowthfactor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy .
Threo-Chloramphenicol-d6 is the deuterium labeled Chloramphenicol[1]. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascularendothelialgrowthfactor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research[2][3][4].
VEGFA Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 27 kDa, targeting to VEGFA. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.
PLGF Antibody (YA1812) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1812), targeting PLGF, with a predicted molecular weight of 25 kDa (observed band size: 23 kDa). PLGF Antibody (YA1812) can be used for WB, ICC/IF, IHC-P experiment in human, mouse, rat background.
VEGFR2 Antibody is a non-conjugated IgG antibody, targeting VEGFR2, with a predicted molecular weight of 152 kDa. VEGFR2 Antibody (YA1388) can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA experiment in human, mouse background.
VEGFB Antibody (YA2627) is a non-conjugated IgG antibody, targeting VEGFB, with a predicted molecular weight of 22 kDa (observed band size: 16-62 kDa). VEGFB Antibody (YA2627) can be used for WB experiment in human, mouse background.
PGF Antibody (YA1434) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1434), targeting PGF. PGF Antibody (YA1434) can be used for FC, ELISA experiment in human background.
Neuropilin 1 Antibody (YA1831) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1831), targeting Neuropilin 1, with a predicted molecular weight of 103 kDa (observed band size: 125-135 kDa). Neuropilin 1 Antibody (YA1831) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.
Pegaptanib sodium is an RNA aptamer directed against vascularendothelialgrowthfactor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascularendothelialgrowthfactor (VEGF). It is widely accepted that vascularendothelialgrowthfactor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
Bevasiranib is a siRNA designed to silence the genes that produce vascularendothelialgrowthfactor (VEGF). It is widely accepted that vascularendothelialgrowthfactor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
Inquiry Online
Your information is safe with us. * Required Fields.
